
Q4 FY2022

Earnings Conference Call

Financial Results & Outlook



February 16, 2023

Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements include EPS guidance and are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations. Forward looking statements include the overall impact of the Novel Coronavirus Disease 2019 (COVID-19) on the Company, its results of operations, liquidity and financial condition (including any estimates of the impact on these items), the rate and consistency with which dental and other practices resume or maintain normal operations in the United States and internationally, expectations regarding personal protective equipment (“PPE”) and COVID-19 related product sales and inventory levels, whether additional resurgences or variants of the virus will adversely impact the resumption of normal operations, whether supply chain disruptions will adversely impact our business, the impact of restructuring programs as well as of any future acquisitions, general economic conditions including exchange rates, inflation and recession, and more generally current expectations regarding performance in current and future periods. Forward looking statements also include the (i) ability of the Company to have continued access to a variety of COVID-19 test types, expectations regarding COVID-19 test sales, demand and inventory levels, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not been, or will not have been, independently verified under normal FDA procedures and (ii) potential for the Company to distribute the COVID-19 vaccines and ancillary supplies.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: risks associated with COVID-19 and any variants thereof, as well as other disease outbreaks, epidemics, pandemics, or similar wide-spread public health concerns and other natural disasters; our dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; legal, regulatory, compliance, cybersecurity, financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; the repeal or judicial prohibition on implementation of the Affordable Care Act; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global and domestic macroeconomic and political conditions, including inflation, deflation, recession, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to other economic indicators, international trade agreements, potential trade barriers and terrorism; failure to comply with existing and future regulatory requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation; risks related to product liability, intellectual property and other claims; litigation risks; new or unanticipated litigation developments and the status of litigation matters; risks associated with customs policies or legislative import restrictions; cyberattacks or other privacy or data security breaches; risks associated with our global operations; our dependence on our senior management, employee hiring and retention, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.

Included within the presentation are non-GAAP financial measures that supplement the Company’s Consolidated Statements of Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company’s actual results prepared under GAAP to exclude certain items. In the presentation appendix, the non-GAAP measures have been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.

Agenda

01 Q4 Overview

02 Q4 Financial Results

03 FY2023 Guidance



Henry Schein

The Leading Provider of Health Care Products and Related Services to Office-based Dental and Medical Practitioners and Alternate Care Sites*

\$12.6B

FY2022 Global
Net Sales

SERVING MORE THAN
1 MILLION
CUSTOMERS

MORE THAN
22,000
TEAM SCHEIN MEMBERS

90 YEARS IN
BUSINESS

OPERATIONS IN
32 COUNTRIES

COMPONENT OF
S&P 500® INDEX
6 YEARS



Recognized for
22
YEARS



Recognized for
11
YEARS



Recognized for
7
YEARS

* Excludes specialty drugs

Our BOLD+1 Strategic Priorities



BUILD complementary software, specialty, and services businesses for high growth



LEVERAGE One Schein to broaden and deepen relationships with our customers and expand customer spend through our product portfolio

+1 CREATE VALUE for our Stakeholders



OPERATIONALIZE One Distribution to deliver exceptional customer experience, increased efficiency and sales growth



DRIVE digital transformation for our customers and for Henry Schein



Our Q4 Results:

- **We closed out 2022 with a very good fourth quarter in which we continued to execute effectively on our 2022 to 2024 Strategic Plan goals**, achieving strong growth in earnings for the fourth quarter and the full year, despite macroeconomic and foreign exchange headwinds.
- **We experienced global growth across our business**, and overall, our solid financial results for the quarter reflect stability in the markets we serve.
- **Excluding sales of PPE products and COVID-19 test kits and adjusting for the 53rd sales week, we achieved very good internal sales growth of 5.0% in local currencies**, driven by excellent growth in our Medical business as well as growth within our Technology and Value-added Services businesses.



Fourth Quarter Financial Results

- Total Sales growth of 1.2% with LCI* Sales decreasing by 1.8%
 - *Total Sales growth impacted by market declines in PPE pricing and lower demand for COVID-19 test kits, as well as a strong US dollar*
 - *Worldwide LCI Sales growth of 5.0% when excluding sales of PPE & COVID-19 Test Kits and adjusting for the 53rd week*
- GAAP diluted EPS of \$0.34
- Non-GAAP diluted EPS of \$1.21
- Introducing guidance for 2023 (refer to slide 14)



*LCI reflects internally generated sales in local currencies excluding acquisitions from the prior twelve months as well as adjusting for the 53rd week in Q4 FY2022.

Q4 FY2022 Worldwide Summary*

<i>\$ Millions except EPS</i>	Q4 FY2022 (GAAP)	Q4 FY2021 (GAAP)	Q4 FY2022 (Non-GAAP)	Q4 FY2021 (Non-GAAP)
Total Sales	\$3,371	\$3,331	\$3,371	\$3,331
Operating Income	\$72	\$201	\$227	\$206
Operating Margin	2.15%	6.02%	6.74%	6.18%
Diluted EPS	\$0.34	\$1.05	\$1.21	\$1.07

*Refer to slide 21 for our GAAP & Non-GAAP Reconciliation.

**Adjusted for the 53rd week in Q4 FY2022.

HIGHLIGHTS

Solid underlying LCI sales growth of 5.0%** (excluding PPE and COVID-19 Test Kits) across our businesses. Excellent growth in our Medical business as well as growth in our Technology/VAS businesses

Operating Income growth (Non-GAAP) resulting from Gross Margin expansion y/y and lower operating expenses as a percentage of sales


+56 basis point improvement y/y on a Non-GAAP basis

13.1% growth y/y on a Non-GAAP basis

Q4 FY2022 Worldwide Sales Summary

\$ Millions	Q4 FY2022	Q4 FY2021	y/y Δ	y/y LCI* Δ
Global Dental	\$2,007	\$2,020	-0.7%	-2.6%
<i>Excl. PPE</i>			2.9%	0.9%
Global Medical	1,177	1,132	4.1%	-1.3%
<i>Excl. PPE/COVID-19 Test Kits</i>			20.5%	14.3%
Global Technology/VAS	187	179	4.6%	3.4%**
Total Sales	\$3,371	\$3,331	1.2%	-1.8%
<i>Excl. PPE/COVID-19 Test Kits</i>			8.2%	5.0%

BY GEOGRAPHY



*LCI reflects internally generated sales in local currencies excluding acquisitions from the prior twelve months as well as adjusting for the 53rd week in Q4 FY2022.

9 **Global Technology/VAS Sales LCI growth was 9.1% after adjusting for the expiration of a Government contract.

Q4 FY2022 Global Dental Sales Summary

\$ Millions	Q4 FY2022	Q4 FY2021	y/y Δ	y/y LCI* Δ
North America Dental Consumables	\$917	\$901	1.7%	-5.1%
<i>Excl. PPE</i>			8.5%	1.3%
North America Dental Equipment	351	316	10.8%	1.3%
North America Dental	\$1,268	\$1,217	4.1%	-3.4%
International Dental Consumables	\$554	\$609	-9.0%	-1.7%
<i>Excl. PPE</i>			-6.7%	0.7%
International Dental Equipment	185	194	-4.4%	-0.4%
International Dental	\$739	\$803	-7.9%	-1.4%
Global Dental Consumables	\$1,471	\$1,510	-2.6%	-3.7%
<i>Excl. PPE</i>			2.1%	1.0%
Global Dental Equipment	536	510	5.0%	0.7%
Global Dental	\$2,007	\$2,020	-0.7%	-2.6%
<i>Excl. PPE</i>			2.9%	0.9%

Dental performance driven by growth in North America Consumable Sales excluding PPE as well as in North America Equipment sales.

Consumables LCI growth excl. PPE was 1.3% in North America Dental and 0.7% in International Dental.

Equipment LCI growth was 1.3% in North America Dental.

Q4 FY2022 Global Medical Sales Summary

<i>\$ Millions</i>	Q4 FY2022	Q4 FY2021	y/y Δ	y/y LCI* Δ
North America Medical	\$1,160	\$1,107	4.8%	-0.9%
International Medical	17	25	-26.0%	-19.7%
Global Medical	\$1,177	\$1,132	4.1%	-1.3%
<i>Excl. PPE/COVID-19 Test Kits</i>			20.5%	14.3%
COVID-19 Test Kits (Worldwide)	\$93	\$187	-50.4%	-53.0%

Continued strength in Medical sales led by sales of Non-PPE/COVID-19 Test Kits in North America reflecting higher patient traffic to alternate care sites.

Sales LCI growth excl. PPE and COVID-19 Test Kits was 14.3%.

Medical performance driven by sales of point-of-care diagnostic, medical equipment and pharmaceutical sales.

Q4 FY2022 Technology/VAS Sales Summary

<i>\$ Millions</i>	Q4 FY2022	Q4 FY2021	y/y Δ	y/y LCI* Δ
North America Technology/VAS	\$164	\$156	5.2%	2.1%
International Technology/VAS	23	23	0.6%	12.2%
Global Technology/VAS	\$187	\$179	4.6%	3.4%

Solid sales growth exhibited by Henry Schein One, particularly in our International businesses and North America practice management software.

Sales growth was negatively impacted by the expiration of a government contract. Adjusting for this contract, North America Technology/VAS LCI growth was 8.6% and Global Technology/VAS LCI growth was 9.1% due to Dentally cloud-based solution.

Q4 FY2022

Technology/VAS + Dental Specialty Sales Summary

<i>\$ Millions</i>	Q4 FY2022	Q4 FY2021	y/y Δ	y/y LCI** Δ
Global Technology/VAS	\$187	\$179	4.6%	3.4%
Global Dental Specialties*	247	245	1.0%	0.3%
Global Technology/VAS + Dental Specialties	\$434	\$424	2.5%	1.6%
% of Total Sales	12.9%	12.7%		

Our goal is to grow Sales of Technology/VAS + Dental Specialty businesses in the low double-digits, including acquisitions, with minimum of 20% Operating Margin.

*Dental Specialties consists of our Implants & Biomaterials, Orthodontics and Endodontics businesses and is included within our Health Care Distribution Segment.

**LCI reflects internally generated sales in local currencies excluding acquisitions from the prior twelve months as well as adjusting for the 53rd week in Q4 FY2022.

Financial Guidance – Full Year 2023

We are introducing financial guidance for 2023, which reflects the impact of lower selling prices of PPE products and reduced demand for COVID-19 test kits.

These headwinds are largely offset by earnings momentum in our underlying core businesses, and we expect non-GAAP operating income will grow in the high single-digit to low double-digit range when excluding the contribution from PPE products and COVID-19 test kits.

As of February 16, 2023*	FY2023
Total Sales growth over 2022**	1% to 3%
PPE Sales decline compared with 2022	-20% to -25%
COVID-19 Test Kit Sales decline compared with 2022	-35% to -40%
2023 Non-GAAP Operating Margin change compared with 2022 Non-GAAP Operating Margin***	-10 bps to -15 bps
2023 Non-GAAP diluted EPS***	\$5.25 to \$5.42
2023 Non-GAAP diluted EPS growth compared with 2022 Non-GAAP diluted EPS***	-2% to +1%
Impact on 2023 non-GAAP diluted EPS from lower contributions to earnings from sales of PPE products and COVID-19 test kits	\$0.35 to \$0.40

*FY2023 Guidance is as of February 16, 2023 and should not be considered an update of guidance beyond that date. Guidance for 2023 is for completed or previously announced acquisitions and does not include potential future acquisitions. As our strategic plan focuses on investing in higher growth businesses that have a larger intangible asset component, we believe earnings excluding intangible asset amortization better represents the underlying business results. Therefore, 2023 non-GAAP guidance excludes the effects of acquisition intangible asset amortization expense and integration and restructuring expenses. This guidance also assumes that foreign currency exchange rates will remain generally consistent with current levels, end markets will remain consistent with current market conditions and that there are no material adverse market changes associated with COVID-19.

**Please note that 2022 included one extra selling week compared with 2023, which occurred in the fourth quarter.


***2023 Non-GAAP guidance excludes amortization from acquired intangible assets. Refer to slide 22 for GAAP & Non-GAAP Reconciliation.



PPE and COVID-19 Test Kit Sales

Significant reduction in PPE and COVID-19 Test Kit Sales since 2021 (~\$900M lower sales)*

Sales (\$M):



PPE products and COVID test kits helped sales recovery in 2020 and 2021


Provided a significant headwind to sales growth in 2022 and 2023E

Sales expected to stabilize by 2024

Impact of PPE and COVID-19 Test Kit Sales on EPS

Lower Sales of PPE and COVID-19 Test Kits reduce non-GAAP EPS growth*

Non-GAAP EPS (\$):



Non-GAAP EPS

2023 Guidance:

- 5% - 8% implied increase from the underlying business

ESG Action & Reporting



Environmental

- Issued our first TCFD Report with TCFD Scenario Analysis
- Working on SBTi readiness and climate roadmap towards our carbon reduction goal.
- Launched in EMEA January 2023 the new **Practice Green** brand to encourage customers to become more eco-friendly and to help empower the health care community to establish sustainable practices for a healthier planet



Social

- Continued commitment to drive a culture of overall wellness to support TSM wellbeing through education and resources
- Published EEO-1 Data
- New goal and initiatives to **increase the diversity of all underrepresented groups** in senior leadership roles
- Commitment to donate \$50M in cash and product by 2025 to advance health equity. **To date, donated over \$21.5M to expand access to care for underserved and underrepresented communities.**
- Launched Human Rights Statement and launching a human rights compliance training course for 2023.



Governance

- Issued 2021 Sustainability and CSR Report per SASB and GRI reporting framework
- **ESG Assurance Readiness complete** with teams enhancing internal controls and data collection methods
- **Environmental Impact Council activated** with Board and EMC engagement.

Appendix



Q4 FY2022

PPE & COVID-19 Test Kit Sales Summary

<i>\$ Millions</i>	Q4 FY2022	Q4 FY2021	y/y Δ	y/y LCI* Δ
North America Dental Consumables PPE	\$71	\$122	-41.6%	-45.5%
Int'l Dental Consumables PPE	24	40	-40.9%	-36.0%
Global Medical PPE & COVID-19 Test Kits	159	286	-44.5%	-47.4%
Total PPE & COVID-19 Test Kits	\$254	\$448	-43.4%	-45.8%

Prior Non-GAAP Reporting to New Non-GAAP Reporting Reconciliation

	Full Year			2021					2022				
	2018 Actual	2019 Actual	2020 Actual	Q1 Actual	Q2 Actual	Q3 Actual	Q4 Actual	FY Actual	Q1 Actual	Q2 Actual	Q3 Actual	Q4 Actual	FY Actual
(\$ in millions)													
Operating Income - Prior Reporting	\$ 693	\$ 733	\$ 588	\$ 246	\$ 214	\$ 210	\$ 206	\$ 876	\$ 244	\$ 220	\$ 221	\$ 227	\$ 912
y/y change		5.7%	-19.8%					49.1%	-0.5%	2.9%	4.6%	10.4%	4.1%
Acquisition Amortization (Pre-Tax)	\$ 75	\$ 104	\$ 102	\$ 29	\$ 30	\$ 31	\$ 33	\$ 123	\$ 32	\$ 31	\$ 32	\$ 31	\$ 126
Operating Income - New Reporting	\$ 769	\$ 837	\$ 690	\$ 275	\$ 244	\$ 241	\$ 239	\$ 999	\$ 276	\$ 251	\$ 253	\$ 258	\$ 1,038
y/y change		8.9%	-17.6%					44.8%	0.4%	3.0%	4.5%	8.1%	3.9%
Operating Margin - Prior Reporting	7.36%	7.34%	5.81%	8.40%	7.21%	6.63%	6.18%	7.06%	7.69%	7.27%	7.18%	6.74%	7.21%
y/y change		-2 bp	-153 bp					125 bp	-71 bp	6 bp	55 bp	56 bp	15 bp
Acquisition Amortization (Margin)	0.80%	1.04%	1.01%	1.02%	1.01%	0.96%	0.98%	0.99%	1.01%	1.03%	1.03%	0.91%	0.99%
Operating Margin - New Reporting	8.16%	8.38%	6.82%	9.41%	8.23%	7.59%	7.16%	8.06%	8.70%	8.30%	8.21%	7.65%	8.20%
y/y change		22 bp	-156 bp					124 bp	-71 bp	7 bp	62 bp	49 bp	14 bp
Non-GAAP Net Income (Prior Reporting)	\$ 486	\$ 523	\$ 436	\$ 177	\$ 157	\$ 155	\$ 151	\$ 640	\$ 180	\$ 161	\$ 157	\$ 165	\$ 663
y/y change		7.8%	-16.7%					46.7%	1.8%	2.3%	1.5%	9.3%	3.6%
Acquisition Amortization (After-Tax & NCI)	\$ 68	\$ 90	\$ 69	\$ 18	\$ 19	\$ 19	\$ 20	\$ 76	\$ 20	\$ 19	\$ 20	\$ 19	\$ 78
Non-GAAP Net Income (New Reporting)	\$ 553	\$ 613	\$ 505	\$ 195	\$ 176	\$ 174	\$ 171	\$ 716	\$ 200	\$ 180	\$ 177	\$ 184	\$ 741
y/y change		10.8%	-17.7%					41.8%	2.4%	2.4%	2.0%	7.6%	3.5%
Non-GAAP EPS (Prior Reporting)	\$ 3.16	\$ 3.51	\$ 3.04	\$ 1.24	\$ 1.11	\$ 1.10	\$ 1.07	\$ 4.51	\$ 1.30	\$ 1.16	\$ 1.15	\$ 1.21	\$ 4.81
y/y change		11.1%	-13.4%					48.4%	4.8%	4.5%	4.5%	13.1%	6.7%
Acquisition Amortization (EPS)	\$ 0.44	\$ 0.60	\$ 0.48	\$ 0.13	\$ 0.13	\$ 0.13	\$ 0.14	\$ 0.54	\$ 0.14	\$ 0.14	\$ 0.14	\$ 0.14	\$ 0.57
Non-GAAP EPS (New Reporting)	\$ 3.60	\$ 4.11	\$ 3.52	\$ 1.36	\$ 1.24	\$ 1.23	\$ 1.22	\$ 5.05	\$ 1.44	\$ 1.30	\$ 1.29	\$ 1.35	\$ 5.38
y/y change		14.2%	-14.4%					43.5%	5.9%	4.8%	4.9%	10.7%	6.5%

Note: Prior periods have been restated to conform to the current period presentation
Amounts may not sum due to rounding

GAAP & Non-GAAP Reconciliations

Q4 FY2022 Financial Highlights

(in millions, except per share data)

	GAAP			Reconciling Items				Non-GAAP Before Amortization Expense from Acquired Intangible Assets			Reconciling Item Amortization Expense from Acquired Intangible		Non-GAAP		
	Q4 2021	Q4 2022	Growth	Restructuring and Integration Costs		Impairment of Intangible Assets		Q4 2021	Q4 2022	Growth	Q4 2021	Q4 2022	2021	2022	Growth
				2021	2022	2021	2022								
Net Sales	\$ 3,331	\$ 3,371	1.2%					\$ 3,331	\$ 3,371	1.2%	\$ -	\$ -	\$ 3,331	\$ 3,371	1.2%
Operating Income	\$ 201	\$ 72	-63.8%	\$ 4	\$ 121	\$ 1	\$ 34	\$ 206	\$ 227	10.4%	\$ 33	\$ 31	\$ 239	\$ 258	8.1%
Operating Margin	6.02%	2.15%	(387) bps					6.18%	6.74%	56 bps			7.16%	7.65%	49 bps
Net Income	\$ 147	\$ 47	-68.2%	\$ 3	\$ 95	\$ 0	\$ 23	151	165	9.3%	\$ 20	\$ 19	\$ 171	\$ 184	7.6%
Diluted EPS	\$ 1.05	\$ 0.34	-67.6%	\$ 0.02	\$ 0.70	\$ -	\$ 0.17	\$ 1.07	\$ 1.21	13.1%	\$ 0.14	\$ 0.14	\$ 1.22	\$ 1.35	10.7%

Notes: Amounts may not sum due to rounding.

Prior periods have been restated to conform to the current period presentation.

This presentation includes both GAAP and non-GAAP financial results. We believe the non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable the comparison of financial results between periods where certain items may vary independently of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding GAAP measures.

GAAP & Non-GAAP Reconciliations

2022 Financial Highlights

(in millions, except per share data)

	GAAP			Reconciling Items								Non-GAAP Before Amortization Expense from Acquired Intangible Assets			Reconciling Item Amortization Expense from Acquired Intangible Assets		Non-GAAP		
	2021	2022	Growth	Restructuring Costs		Settlement and Litigation Costs		Net Gain on Sale of Equity Investment		Impairment of Intangible Assets		2021	2022	Growth	2021	2022	2021	2022	Growth
				2021	2022	2021	2022	2021	2022	2021	2022				2021	2022			
Net Sales	\$ 12,401	\$ 12,647	2.0%								\$ -	\$ -	2.0%	\$ 12,401	\$ 12,647	2.0%	\$ -	\$ -	2.0%
Operating Income	\$ 852	\$ 747	-12.2%	\$ 8	\$ 131	\$ 16	\$ -			\$ 1	\$ 34	4.1%	\$ 876	\$ 912	4.1%	\$ 123	\$ 126	3.9%	
Operating Margin	6.87%	5.91%	(96) bps									7.06%	7.21%	15 bps			8.06%	8.20%	14 bps
Net Income	\$ 631	\$ 538	-14.8%	\$ 5	\$ 103	\$ 11	\$ -	\$ (7)		\$ 0	\$ 23	3.6%	\$ 640	\$ 663	3.6%	\$ 76	\$ 78	3.5%	
Diluted EPS	\$ 4.45	\$ 3.91	-12.1%	\$ 0.03	\$ 0.74	\$ 0.08	\$ -	\$ (0.05)	\$ -	\$ -	\$ 0.16	6.7%	\$ 4.51	\$ 4.81	6.7%	\$ 0.54	\$ 0.57	6.5%	

Notes: Amounts may not sum due to rounding.

Prior periods have been restated to conform to the current period presentation.

This presentation includes both GAAP and non-GAAP financial results. We believe the non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable the comparison of financial results between periods where certain items may vary independently of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding GAAP measures.